You are here

Leukemia Insights: Vol. 16, No. 1 Spring 2011

 

New Strategies for Chronic Myelogenous Leukemia

Despite the major advances in therapy with the successes of imatinib and second-generation tyrosine kinase inhibitors, there is room for improving the management of patients with chronic myelogenous leukemia. Presently, there are clinical trials addressing the different stages of  CML. Some of the available clinical trials are reviewed here.

Presently, there are clinical trials addressing the different stages of  CML. Some of the available clinical trials are reviewed here.

http://mdanderson.bm23.com/public/?q=preview_message&fn=Link&t=1&ssid=5862&id=kmxaqec3zqfgmwxb9rnjevyk3ni1t&id2=9s9sei2nuf2m0ftrm1t4ydtwnv49o&subscriber_id=artmribeijdasbsbwohkytlosoaqbkn&m